Levels of Plasma Immunoglobulin G with Specificity against the Cysteine-Rich Interdomain Regions of a Semiconserved Plasmodium falciparum Erythrocyte Membrane Protein 1, VAR4, Predict Protection against Malarial Anemia and Febrile Episodes

ABSTRACT Antibodies to variant surface antigen have been implicated as mediators of malaria immunity in studies measuring immunoglobulin G (IgG) binding to infected erythrocytes. Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is an important target for these antibodies, but no study has directly linked the presence of PfEMP1 antibodies in children to protection. We measured plasma IgG levels to the cysteine-rich interdomain region 1α (CIDR1α) of VAR4 (VAR4-CIDR1α), a member of a semiconserved PfEMP1 subfamily, by enzyme-linked immunosorbent assay in 561 Tanzanian individuals, who were monitored clinically for 7 months. The participants resided in Mkokola (a high-transmission village where malaria is holoendemic) or Kwamasimba (a moderate-transmission village). For comparison, plasma IgG levels to two merozoite surface protein 1 (MSP1) constructs, MSP1-19 and MSP1 block 2, and a control CIDR1 domain were measured. VAR4-CIDR1α antibodies were acquired at an earlier age in Mkokola than in Kwamasimba, but after the age of 10 years the levels were comparable in the two villages. After controlling for age and other covariates, the risk of having anemia at enrollment was reduced in VAR4-CIDR1α responders for Mkokola (adjusted odds ratio [AOR], 0.49; 95% confidence interval [CI], 0.29 to 0.88; P = 0.016) and Kwamasimba (AOR, 0.33; 95% CI, 0.16 to 0.68; P = 0.003) villages. The risk of developing malaria fever was reduced among individuals with a measurable VAR4-CIDR1α response from Mkokola village (AOR, 0.51; 95% CI, 0.29 to 0.89; P = 0.018) but not in Kwamasimba. Antibody levels to the MSP1 constructs and the control CIDR1α domain were not associated with morbidity protection. These data strengthen the concept of developing vaccines based on PfEMP1.

[1]  Thor G. Theander,et al.  Plasmodium falciparum Variant Surface Antigen Expression Varies Between Isolates Causing Severe and Nonsevere Malaria and Is Modified by Acquired Immunity1 , 2002, The Journal of Immunology.

[2]  T. Theander,et al.  Levels of Antibody to Conserved Parts of Plasmodium falciparum Merozoite Surface Protein 1 in Ghanaian Children Are Not Associated with Protection from Clinical Malaria , 1999, Infection and Immunity.

[3]  A. Holder,et al.  Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (Pf MSP1) of Plasmodium falciparum are associated with reduced malaria morbidity , 1992, Parasite immunology.

[4]  S. Lal,et al.  Epidemiology and control of malaria , 1999, Indian journal of pediatrics.

[5]  I. McGregor,et al.  Gamma-Globulin and Acquired Immunity to Human Malaria , 1961, Nature.

[6]  J C Reeder,et al.  Chondroitin sulfate A is a cell surface receptor for Plasmodium falciparum-infected erythrocytes , 1995, The Journal of experimental medicine.

[7]  J. Venter,et al.  The malaria genome sequencing project: complete sequence of Plasmodium falciparum chromosome 2. , 1999, Parassitologia.

[8]  C. Newbold,et al.  Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for Plasmodium falciparum , 1989, Nature.

[9]  B. Gamain,et al.  The surface variant antigens of Plasmodium falciparum contain cross-reactive epitopes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  David D. Roberts,et al.  Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence , 1985, Nature.

[11]  K. Marsh,et al.  Clinical features and pathogenesis of severe malaria. , 2004, Trends in parasitology.

[12]  D. Cavanagh,et al.  Antigenicity of recombinant proteins derived from Plasmodium falciparum merozoite surface protein 1. , 1997, Molecular and biochemical parasitology.

[13]  A. Saul,et al.  Progress in the development of recombinant and synthetic blood-stage malaria vaccines , 2003, Journal of Experimental Biology.

[14]  T. Theander,et al.  The epidemiology of febrile malaria episodes in an area of unstable and seasonal transmission. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  Kevin Marsh,et al.  Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria , 2004, The Lancet.

[16]  C. Rogier,et al.  Plasmodium falciparum clinical malaria: lessons from longitudinal studies in Senegal. , 1999, Parassitologia.

[17]  Thor G. Theander,et al.  Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria , 2004, The Journal of experimental medicine.

[18]  X. Su,et al.  The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of plasmodium falciparum-infected erythrocytes , 1995, Cell.

[19]  L. Bruce-Chwatt.  A LONGITUDINAL SURVEY OF NATURAL MALARIA INFECTION IN A GROUP OF WEST AFRICAN ADULTS. , 1963, The West African medical journal.

[20]  A. Holder,et al.  A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. , 1998, Journal of immunology.

[21]  May Ho,et al.  Molecular mechanisms of cytoadherence in malaria. , 1999, American journal of physiology. Cell physiology.

[22]  A. Holder,et al.  The Fine Specificity, but Not the Invasion Inhibitory Activity, of 19-Kilodalton Merozoite Surface Protein 1-Specific Antibodies Is Associated with Resistance to Malarial Parasitemia in a Cross-Sectional Survey in The Gambia , 2004, Infection and Immunity.

[23]  D. Conway,et al.  Antibodies to the N-Terminal Block 2 of Plasmodium falciparum Merozoite Surface Protein 1 Are Associated with Protection against Clinical Malaria , 2004, Infection and Immunity.

[24]  C. Newbold,et al.  Plasmodium falciparum-infected erythrocytes: agglutination by diverse Kenyan plasma is associated with severe disease and young host age. , 2000, The Journal of infectious diseases.

[25]  A. Holder,et al.  Fine Specificity of Serum Antibodies to Plasmodium falciparum Merozoite Surface Protein, PfMSP-119, Predicts Protection from Malaria Infection and High-Density Parasitemia , 2004, Infection and Immunity.

[26]  C. Victora,et al.  The silent burden of anaemia in Tanzanian children: a community-based study. , 2003, Bulletin of the World Health Organization.

[27]  S. Christophers.  The Mechanism of Immunity against Malaria in Communities living under Hyper-Endemic Conditions. , 1924 .

[28]  Patrick E. Duffy,et al.  Adherence of Plasmodium falciparum to Chondroitin Sulfate A in the Human Placenta , 1996, Science.

[29]  A. Holder,et al.  Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. , 1996, The Journal of infectious diseases.

[30]  Qijun Chen,et al.  var genes, PfEMP1 and the human host. , 2004, Molecular and biochemical parasitology.

[31]  J. Barnwell,et al.  A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes. , 1989, The Journal of clinical investigation.

[32]  K. Marsh,et al.  Parasite-infected-cell-agglutination and indirect immunofluorescence assays for detection of human serum antibodies bound to antigens on Plasmodium falciparum-infected erythrocytes. , 1986, Journal of immunological methods.

[33]  O. Branch,et al.  A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. , 1998, The American journal of tropical medicine and hygiene.

[34]  B. Gamain,et al.  Classification of adhesive domains in the Plasmodium falciparum erythrocyte membrane protein 1 family. , 2000, Molecular and biochemical parasitology.

[35]  L. Hviid,et al.  Variant surface antigens, virulence genes and the pathogenesis of malaria. , 2004, Trends in parasitology.

[36]  R. Snow,et al.  Severe childhood malaria in two areas of markedly different falciparum transmission in east Africa. , 1994, Acta tropica.

[37]  D. Smith,et al.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. , 1988, Gene.

[38]  T. Theander,et al.  Sub-grouping of Plasmodium falciparum 3D7 var genes based on sequence analysis of coding and non-coding regions , 2003, Malaria Journal.

[39]  A. Sabchareon,et al.  Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. , 1991, The American journal of tropical medicine and hygiene.

[40]  T. Theander,et al.  Detection of antibodies to variant antigens on Plasmodium falciparum-infected erythrocytes by flow cytometry. , 1999, Cytometry.

[41]  S. Sharp,et al.  Plasmodium falciparum Associated with Severe Childhood Malaria Preferentially Expresses PfEMP1 Encoded by Group A var Genes , 2004, The Journal of experimental medicine.

[42]  S. Lindsay,et al.  Relationship Between Altitude and Intensity of Malaria Transmission in the Usambara Mountains, Tanzania , 2003, Journal of medical entomology.

[43]  D. Conway,et al.  Cross-sectional study of specific antibodies to a polymorphic Plasmodium falciparum antigen and of parasite antigen genotypes in school children on the slope of Mount Cameroon. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[44]  A. Holder,et al.  Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. , 1999, Parassitologia.